Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus”

Clinical Pharmacokinetics

Volumn 54, Issue 4, 2015, Pages 447-448

  Raschi, Emanuel ^a   Poluzzi, Elisabetta ^a   De Ponti, Fabrizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; SAXAGLIPTIN; SITAGLIPTIN; VILDAGLIPTIN; GLUCAGON RECEPTOR;

CHRONIC LIVER DISEASE; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; DRUG TRANSFORMATION; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; LIVER INJURY; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SAFETY; PRIORITY JOURNAL; AGONISTS; LIVER DISEASE; METABOLISM;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; LIVER DISEASES; RECEPTORS, GLUCAGON;

EID: 84925539259     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0248-4     Document Type: Letter

References (12)

1. Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014;53:773–85.
2. Barbehenn E, Almashat S, Carome M, Wolfe S. Hepatotoxicity of alogliptin. Clin Pharmacokinet. 2014;53:1055–6.
3. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, EXAMINE Investigators, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.
4. Scheen AJ. Alogliptin: concern about hepatotoxicity? Clin Pharmacokinet. 2014;53:1057–9.
5. Brinker AD, Lyndly J, Tonning J, Moeny D, Levine JG, Avigan MI. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database. Drug Saf. 2013;36:1169–78.
6. Piccinni C, Motola D, Marchesini G, Poluzzi E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care. 2011;34:1369–71.
7. Poluzzi E, Raschi E, Piccinni C, De Ponti F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). In: Karahoca A, editor. Data mining applications in engineering and medicine. Croatia: InTech; 2012. p. 267–301.
8. Raschi E, Poluzzi E, Koci A, Caraceni P, De Ponti F. Assessing liver injury associated with antimycotics: concise literature review and clues from data mining of the FAERS database. World J Hepatol. 2014;6:601–12.
9. Suzuki A, Andrade RJ, Bjornsson E, Lucena MI, Lee WM, Yuen NA, et al. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf. 2010;33:503–22.
10. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51:501–14.
11. US Food and Drug Administration. Product Information: sitagliptin. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021995s028lbl.pdf. Accessed 3 Dec 2014.
12. European Medicines Agency. Summary of product characteristics: sitagliptin. 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000722/WC500039054.pdf. Accessed 3 Dec 2014.